CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 461 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR Adding Tremelimumab to Durvalumab and Chemotherapy Provides Survival Benefit for Patients... November 15, 2022 24-Year-Old Woman with Terminal Breast Cancer Dreams of Fairytale Wedding with... April 16, 2019 College Student Rescues Cats Between Classes, Working 2 Jobs, And Planning... November 5, 2021 11 top tips for cutting back on alcohol January 13, 2022 Load more HOT NEWS Lockdown Keeping Young Mother with Metastatic Breast Cancer from Saying Goodbye... ΚΑΡΚΙΝΟΣ ΣΤΟ ΣΥΚΩΤΙ 2021 ASCO Annual Meeting Research Round Up: Advances in Genitourinary Cancers EMA Recommends Approval of the Marketing Authorisation for Tagraxofusp
